Seebeck and Nernst coefficients of a magnetized hot QCD medium with number conserving kernel

We have studied the thermoelectric response of a hot and magnetized QCD medium created in the noncentral events at heavy-ion collider experiments. The collisional aspects of the medium have been embedded in the relativistic Boltzmann transport equation (RBTE) using Bhatnagar-Gross-Krook (BGK) collision integral, which insures the particle number conservation, unlike the commonly used relaxation time approximation (RTA). We have incorporated the thermal medium effects in the guise of a quasiparticle model, where the interaction among the partons is embodied in the medium dependent mass of the quark, which has been evaluated using the framework of the perturbative thermal QCD with a magnetic field in the background. In the absence of $B$, the Seebeck coefficient for individual quark flavors gets slightly reduced in the BGK term in comparison to naive RTA, while it gets enhanced for the composite partonic medium. In the presence of strong magnetic field ($B$), the BGK term enhances the Seebeck coefficient for the individual flavors as well as that for medium. The medium Seebeck coefficient rises with the strength of quark chemical potential ($\mu$) in the absence as well as that in the strong $B$. We observe chirality dependence in the Seebeck and Nernst coefficients in the weak magnetic field as the degeneracy in the masses of left- and right-handed chiral modes gets lifted in the weak $B$. Seebeck coefficient is larger for left-handed modes contrary to the Nernst coefficient which is higher for the right-handed modes. Seebeck coefficient is almost similar in the weak field for both the collision term, while Nernst coefficient gets reduced (enhanced) for $L$ ($R$) modes considerably in the BGK collision term.Comment: 32 pages, 24 figure

Thermoelectric response of a hot and weakly magnetized anisotropic QCD medium

We have studied the Seebeck and Nernst coefficients of a weakly magnetized hot QCD medium having a weak momentum anisotropy within the kinetic theory approach. The thermal medium effects have been incorporated in the framework of a quasi-particle model where the medium dependent mass of the quark has been calculated using perturbative thermal QCD in the presence of a weak magnetic field which leads to different masses for the left ($L$) and right ($R$) handed chiral quark modes. We have found that the Seebeck and Nernst coefficient magnitudes for the individual quark flavors as well as for the composite medium are decreasing functions of temperature and decreasing functions of anisotropy strength. The Nernst coefficient magnitudes are about an order of magnitude smaller than their Seebeck counterparts, indicating the Seebeck effect constitutes a stronger response than the Nernst effect. The average percentage change corresponding to switching between quasiparticle modes ($L\to R$ or $R\to L$) is an order of magnitude smaller for Nernst coefficients, compared to the Seebeck coefficients.Comment: 26 pages, 15 figure

Shear viscosity of rotating, hot, and dense spin-half fermionic systems from quantum field theory

In this study, we calculate the shear viscosity for rotating fermions with spin-half under conditions of high temperature and density. We employ the Kubo formalism, rooted in finite-temperature quantum field theory, to compute the field correlation functions essential for this evaluation. The one-loop diagram pertinent to shear viscosity is analyzed within the context of curved space, utilizing tetrad formalism as an effective approach in cylindrical coordinates. Our findings focus on extremely high angular velocities, ranging from 0.1 to 1 GeV, which align with experimental expectations. Furthermore, we explore the interrelationship between the chemical potential and angular velocity within the scope of this study.Comment: 14 pages, 4 figure

The influence of geometrical shapes of stenosis on the blood flow in stenosed artery

The present work was carried out to investigate the blood flow behavior and the severity of blockage caused in the arterial passage due to the different geometries such as elliptical, trapezium and triangular shapes of stenosis. The study was conducted with respect to various sizes of stenosis in terms of 70%, 80% and 90% area blockage of the arterial blood flow. The study was carried out numerically with the help of advance computational fluid dynamic software. It was found that the shape of the stenosis plays an important role in overall pressure drop across the blockage region of artery. The highest level of pressure drop was observed for trapezoidal shape of stenosis followed by elliptical and then by triangular shaped stenosis. The wall shear stress across the stenosis is great for trapezoidal shape followed by triangular and elliptical stenosis for same blockage area in the artery

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Dynamics of Hot QCD Matter -- Current Status and Developments

The discovery and characterization of hot and dense QCD matter, known as Quark Gluon Plasma (QGP), remains the most international collaborative effort and synergy between theorists and experimentalists in modern nuclear physics to date. The experimentalists around the world not only collect an unprecedented amount of data in heavy-ion collisions, at Relativistic Heavy Ion Collider (RHIC), at Brookhaven National Laboratory (BNL) in New York, USA, and the Large Hadron Collider (LHC), at CERN in Geneva, Switzerland but also analyze these data to unravel the mystery of this new phase of matter that filled a few microseconds old universe, just after the Big Bang. In the meantime, advancements in theoretical works and computing capability extend our wisdom about the hot-dense QCD matter and its dynamics through mathematical equations. The exchange of ideas between experimentalists and theoreticians is crucial for the progress of our knowledge. The motivation of this first conference named "HOT QCD Matter 2022" is to bring the community together to have a discourse on this topic. In this article, there are 36 sections discussing various topics in the field of relativistic heavy-ion collisions and related phenomena that cover a snapshot of the current experimental observations and theoretical progress. This article begins with the theoretical overview of relativistic spin-hydrodynamics in the presence of the external magnetic field, followed by the Lattice QCD results on heavy quarks in QGP, and finally, it ends with an overview of experiment results.Comment: Compilation of the contributions (148 pages) as presented in the `Hot QCD Matter 2022 conference', held from May 12 to 14, 2022, jointly organized by IIT Goa & Goa University, Goa, Indi

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention